23andMe Is Under Fire. Its Founder Remains ‘Optimistic’
You had an exclusive partnership with GlaxoSmithKline for five years, from 2018 to 2023. How successful was that? It was overwhelmingly productive. Fifty drug targets came out of it, far more than we expected. They upped it again for one more year, the sixth year, though it’s non-exclusive now. We now have the ability to … Read more
